Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi-centric hospital-based case-control study

Bhatnagar, Tarun; Chaudhuri, Sirshendu; Ponnaiah, Manickam; Yadav, Pragya; Sabarinathan, R.; Sahay, Rima R.; Ahmed, Faheem; Sreedevi, Aswathy; Bhardwaj, Pankaj; Bilimale, Anil S.; Kumar, Muthusamy Santhosh; Logaraj, M; Narlawar, Uday; Palanivel, C; Patel, Prakash; Sanjay, K; Saxena, Vartika; Singh, Arvind Kumar; Thangaraj, Jeromie Wv; Agarwal, Ashwini; Alvi, Yasir; Amoghashree, .; Ashok, P. P.; Babu, Dinesh; Bahurupi, Yogesh; Bhalavi, Sangita; Behera, Priyamadhaba; Biswas, Priyanka Pandit; Charan, Jaykaran; Chauhan, Nishant Kumar; Chetak, K B; Dar, Lalit; Das, Ayan Kumar; Deepashree, R; Dhar, Minakshi; Dhodapkar, Rahul; Dipu, T S; Dudeja, Mridu; Dudhmal, Manisha; Gadepalli, Ravisekhar; Garg, Mahendra Kumar; Gayathri, A V; Goel, Akhil Dhanesh; Gowdappa, H Basavana; Guleria, Randeep; Gupta, Manoj Kumar; Islam, Farzana; Jain, Mansi; Jain, Vineet; Jawahar, M Lanord Stanley; Joshi, Rajendra; Kar, Sitanshu Sekhar; Kalita, Deepjyoti; Khapre, Meenakshi; Khichar, Satyendra; Kombade, Sarika P; Kohli, Sunil; Kumar, Abhinendra; Kumar, Anil; Kumar, Deepak; Kulirankal, Kiran G; Leela, K V; Majumdar, Triparna; Mishra, Baijayantimala; Misra, Puneet; Misra, Sanjeev; Mohapatra, Prasanta Raghab; Murthy, M Narayana; Nyayanit, Dimpal A; Patel, Manish; Pathania, Monika; Patil, Savita; Patro, Binod Kumar; Ramniwas,; Rathod, Pragati; Shah, Naimesh; Shete, Anita M.; Shukla, Deepak; Shwethashree, M; Sinha, Smita; Surana, Ashish; Trikha, Anjan; Tejashree, A; Venkateshan, Mahalingam; Vijaykrishnan, G; Wadhava, Sarita; Wig, Naveet; Gupta, Nivedita; Abraham, Priya; Murhekar, Manoj

doi:10.1016/j.ijid.2022.07.033

Cited by 32 publications

(23 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both the vaccines employing either the whole virus or spike protein contributed to breakthrough infections. Similar to other reports, significant breakthrough infections were noted even after receiving 2 doses ( 29 ) emphasizing need for a third dose or an early booster. Based on our study it may be surmised that the population without any comorbidity may benefit from the current vaccines.…”

Section: Discussionsupporting

confidence: 89%

SARS-CoV-2 breakthrough infections during the second wave of COVID-19 at Pune, India

Doke

Mhaske

Oka

et al. 2023

Front. Public Health

View full text Add to dashboard Cite

Breakthrough infections following SARS-CoV-2 vaccination remain the global concern. The current study was conducted during the second wave of COVID-19 (1st March−7th July 2021) in Pune, India, at two tertiary care hospitals. Of the 6,159 patients diagnosed as COVID-19, 372/2,210 (16.8%) were breakthrough infections. Of these, 81.1 and 18.8% received one or two doses of Covishield or Covaxin, respectively. Of note, 30.7% patients were with comorbidities, hypertension being the commonest (12.44%). The majority of infections were mild (81.2%). Forty-three patients with breakthrough infections were hospitalized with severe (n = 27, 62.8%) or moderate (n = 16, 37.2%) disease. The receptor binding domain (RBD) sequences from vaccinated (n = 126) and non-vaccinated (n = 168) samples were used for variant analysis. The delta variant was predominant followed by kappa in both vaccinated and non-vaccinated groups. Viral load (qRT-PCR) was not different among these categories. Full-genome comparisons of sequences in relation to vaccination status did not identify any mutation characteristic of the vaccinated group. Irrespective of the number of doses, neutralizing antibody titers (PRNT50) during the first week of clinical disease were higher in the vaccinated patients than the unvaccinated category. In conclusion, though not completely, SARS-CoV-2 vaccines used for country-wide immunization did reduce disease severity among the individuals without any comorbidity by inducing rapid immune response against distinctly different delta and kappa variants. The utility against emerging variants with further mutations need to be carefully examined.

show abstract

Section: Discussionsupporting

confidence: 89%

SARS-CoV-2 breakthrough infections during the second wave of COVID-19 at Pune, India

Doke

Mhaske

Oka

et al. 2023

Front. Public Health

View full text Add to dashboard Cite

show abstract

“…In addition, the effectiveness of seven representative, widely used vaccines against the pandemic strains B.1.617.2 and B.1.1.529 is summarized in Table 2 [ [71] , [72] , [73] , [74] , [75] , [76] , [77] , [78] , [79] , [80] , [81] , [82] , [83] , [84] , [85] , [86] , [87] , [88] , [89] , [90] , [91] , [92] , [93] , [94] , [95] , [96] , [97] , [98] , [99] , [100] , [101] , [102] ]. Vaccine effectiveness appears to be much lower against these recent variants than against the original D614G (B.1) strain.…”

Section: Immunoprotection and Vaccine Inoculationmentioning

confidence: 99%

Evaluation of immunoprotection against coronavirus disease 2019: Novel variants, vaccine inoculation, and complications

Jiang

et al. 2023

Journal of Pharmaceutical Analysis

View full text Add to dashboard Cite

“…However, another study was performed to determine the effectiveness of Covaxin against the Delta variant. The efficacy of the vaccine was 64% after two doses and 44% after one dose, respectively [ 85 ]. This can conclude that Covaxin is a moderately effective vaccine, but it might not fully protect individuals against the new mutant strains.…”

Section: Effectiveness Of Sars-cov-2 Vaccinesmentioning

confidence: 99%

COVID-19 Vaccines, Effectiveness, and Immune Responses

Abufares

Alsoud

Alqudah

et al. 2022

IJMS

View full text Add to dashboard Cite

The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has captivated the globe’s attention since its emergence in 2019. This highly infectious, spreadable, and dangerous pathogen has caused health, social, and economic crises. Therefore, a worldwide collaborative effort was made to find an efficient strategy to overcome and develop vaccines. The new vaccines provide an effective immune response that safeguards the community from the virus’ severity. WHO has approved nine vaccines for emergency use based on safety and efficacy data collected from various conducted clinical trials. Herein, we review the safety and effectiveness of the WHO-approved COVID-19 vaccines and associated immune responses, and their impact on improving the public’s health. Several immunological studies have demonstrated that vaccination dramatically enhances the immune response and reduces the likelihood of future infections in previously infected individuals. However, the type of vaccination and individual health status can significantly affect immune responses. Exposure of healthy individuals to adenovirus vectors or mRNA vaccines causes the early production of antibodies from B and T cells. On the other hand, unhealthy individuals were more likely to experience harmful events due to relapses in their existing conditions. Taken together, aligning with the proper vaccination to a patient’s case can result in better outcomes.

show abstract

Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi-centric hospital-based case-control study

Cited by 32 publications

References 25 publications

SARS-CoV-2 breakthrough infections during the second wave of COVID-19 at Pune, India

SARS-CoV-2 breakthrough infections during the second wave of COVID-19 at Pune, India

Evaluation of immunoprotection against coronavirus disease 2019: Novel variants, vaccine inoculation, and complications

COVID-19 Vaccines, Effectiveness, and Immune Responses

Contact Info

Product

Resources

About